We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
+$170M
Cap. Flow
+$163M
Cap. Flow %
46.98%
Top 10 Hldgs %
43.57%
Holding
90
New
39
Increased
14
Reduced
5
Closed
27

Top Buys

1
ACOR
Acorda Therapeutics
ACOR
+$8.81M
2
EW icon
Edwards Lifesciences
EW
+$8.72M
3
BIIB icon
Biogen
BIIB
+$7.91M
4
BLUE
bluebird bio
BLUE
+$7.43M
5
CNMD icon
CONMED
CNMD
+$7.41M

Top Sells

1
CELG
Celgene Corp
CELG
+$6.74M
2
PACB icon
Pacific Biosciences
PACB
+$5.95M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.68M
4
SAGE
Sage Therapeutics
SAGE
+$5.34M
5
IHF icon
iShares US Healthcare Providers ETF
IHF
+$4.82M

Sector Composition

1 Healthcare 56.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$17.1B
$1.33M 0.38%
+100,000
New +$1.54M
GILD icon
52
Gilead Sciences
GILD
$167B
$1.25M 0.36%
+15,000
New +$1.33M
TNDM icon
53
Tandem Diabetes Care
TNDM
$1.17B
$1.13M 0.33%
15,000
– –
CRBP icon
54
Corbus Pharmaceuticals
CRBP
$167M
$897K 0.26%
+10,000
New +$784K
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$735K 0.21%
+20,000
New +$706K
MDVN
56
DELISTED
MEDIVATION, INC.
MDVN
$633K 0.18%
+10,500
New +$595K
AKTX
57
Akari Therapeutics
AKTX
$19.3M
$629K 0.18%
58
– –
IMMU
58
CALL
DELISTED
Immunomedics Inc
IMMU
$464K 0.13%
+200,000
New +$668K
HRTX icon
59
Heron Therapeutics
HRTX
$89.1M
$451K 0.13%
25,000
– –
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$410K 0.12%
75,000
-175,000
-70% -$2.79M
SYRE icon
61
Spyre Therapeutics
SYRE
$8.7B
$243K 0.07%
+2,000
New +$383K
SGYP
62
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$84K 0.02%
+22,000
New +$74.6K
OCRX
63
DELISTED
Ocera Therapeutics, Inc.
OCRX
$68K 0.02%
35,801
-9,199
-20% -$24.2K
ABBV icon
64
CALL
AbbVie
ABBV
$450B
– –
-100,000
Closed -$5.71M
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-75,000
Closed -$2.1M
ACAD icon
66
PUT
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-350,000
Closed -$9.79M
ADAP
67
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-50,000
Closed -$407K
AGIO icon
68
Agios Pharmaceuticals
AGIO
$2.36B
– –
-140,000
Closed -$5.68M
BHC icon
69
CALL
Bausch Health
BHC
$1.8B
– –
-100,000
Closed -$2.63M
DBVT
70
DBV Technologies
DBVT
$870M
– –
-4,500
Closed -$2.58M
EW icon
71
CALL
Edwards Lifesciences
EW
$49.4B
– –
-300,000
Closed -$8.82M
IART icon
72
Integra LifeSciences
IART
$1.5B
– –
-100,000
Closed -$3.37M
IHE icon
73
iShares US Pharmaceuticals ETF
IHE
$1.27B
– –
-29,400
Closed -$1.34M
IHF icon
74
iShares US Healthcare Providers ETF
IHF
$1.19B
– –
-197,500
Closed -$4.82M
IHI icon
75
iShares US Medical Devices ETF
IHI
$3.03B
– –
-150,000
Closed -$3.06M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Ghost Tree Capital held 90 positions worth $346M, up 96% from $177M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital deployed $163M of net new capital in Q2 2016, opening 39 new positions and adding to 14 existing holdings. Its largest new stake was Acorda Therapeutics: 2,708 shares worth $8.29M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $6.74M trimmed.

  • Ghost Tree Capital's largest Q2 2016 buy was Acorda Therapeutics: 2,708 shares worth $8.29M.
  • Ghost Tree Capital added most to Alexion Pharmaceuticals in Q2 2016, an estimated $7.09M increase.
  • Ghost Tree Capital's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $6.74M.
  • Ghost Tree Capital fully exited Pacific Biosciences in Q2 2016, selling an estimated $5.95M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $346M portfolio in Q2 2016.
  • Ghost Tree Capital opened 39 new positions and closed 27 in Q2 2016.
  • Ghost Tree Capital's portfolio value rose 96% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.